Published in Clin Pharmacol Ther on August 06, 2008
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Pharmacogenomics in the clinic. Nature (2015) 1.71
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One (2012) 1.60
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2011) 1.53
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol (2009) 1.23
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2012) 1.03
Chapter 7: Pharmacogenomics. PLoS Comput Biol (2012) 0.96
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol (2014) 0.95
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet (2009) 0.95
Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools. Environ Mol Mutagen (2012) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis (2011) 0.92
Cancer pharmacogenomics. Clin Pharmacol Ther (2011) 0.89
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? Br J Clin Pharmacol (2015) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother (2012) 0.84
Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer (2014) 0.84
Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics (2014) 0.83
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics (2010) 0.83
Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmgenomics Pers Med (2015) 0.82
Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet (2013) 0.82
TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol (2009) 0.82
Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS One (2014) 0.82
Current progress in pharmacogenetics. Br J Clin Pharmacol (2011) 0.82
Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet (2012) 0.81
Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients. Dig Dis Sci (2012) 0.81
ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics. Mutat Res (2013) 0.80
Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant. J Nucleic Acids (2010) 0.80
Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J (2014) 0.80
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev (2015) 0.79
The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core. J Struct Biol (2013) 0.78
Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia. Eur J Clin Pharmacol (2013) 0.78
PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep (2016) 0.77
A Ham1p-dependent mechanism and modulation of the pyrimidine biosynthetic pathway can both confer resistance to 5-fluorouracil in yeast. PLoS One (2013) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver (2015) 0.76
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenomics Pers Med (2016) 0.75
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med (2017) 0.75
A disease spectrum for ITPA variation: advances in biochemical and clinical research. J Biomed Sci (2016) 0.75
Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J (2015) 0.75
Identifying genes that mediate anthracyline toxicity in immune cells. Front Pharmacol (2015) 0.75
Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther (2012) 0.75
Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia. Turk J Haematol (2015) 0.75
Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med (2014) 0.75
The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients. Medicine (Baltimore) (2017) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med (1984) 3.07
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics (2002) 2.68
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
The purine path to chemotherapy. Science (1989) 2.47
Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics (2004) 2.04
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet (2002) 2.03
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet (2007) 1.66
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene (2003) 1.40
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
"Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol (2000) 1.30
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab (2005) 1.29
Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics (2007) 1.27
Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem (2002) 1.18
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol (1995) 1.15
Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol (2006) 1.13
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut (2006) 1.09
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood (2002) 1.08
HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem (2002) 1.01
Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr (1987) 0.98
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem (2005) 0.97
Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J (2007) 0.92
ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut (2005) 0.91
Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2007) 0.90
A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr (1990) 0.88
Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem (2006) 0.87
Genetic studies of human erythrocyte inosine triphosphatase. Biochem Genet (1969) 0.86
Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol (1985) 0.86
Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics (2004) 0.85
Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther Drug Monit (2008) 0.82
CHARMM: the biomolecular simulation program. J Comput Chem (2009) 27.71
Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis (2001) 12.85
Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) (2008) 9.45
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell (1980) 8.10
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Crystal structure of a Y-family DNA polymerase in action: a mechanism for error-prone and lesion-bypass replication. Cell (2001) 5.93
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A (2000) 5.49
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature (2000) 4.63
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A (1998) 3.88
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron (2001) 3.56
High-throughput genotyping with single nucleotide polymorphisms. Genome Res (2001) 3.55
The mammalian sodium channel BNC1 is required for normal touch sensation. Nature (2000) 3.30
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Hardness, softness, and the fukui function in the electronic theory of metals and catalysis. Proc Natl Acad Sci U S A (1985) 3.12
Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell (1999) 2.91
Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ (2000) 2.91
Short-window spectral analysis of cortical event-related potentials by adaptive multivariate autoregressive modeling: data preprocessing, model validation, and variability assessment. Biol Cybern (2000) 2.81
Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol (2001) 2.80
The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines. J Am Chem Soc (1986) 2.64
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Composite active site of an ABC ATPase: MutS uses ATP to verify mismatch recognition and authorize DNA repair. Mol Cell (2001) 2.46
Crystal structure and ATPase activity of MutL: implications for DNA repair and mutagenesis. Cell (1998) 2.46
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP.Met-tRNA(iMet) ternary complexes. Mol Cell Biol (1995) 2.37
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res (2000) 2.32
Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst (2001) 2.27
Identification of a major keratinocyte cell envelope protein, loricrin. Cell (1990) 2.25
Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev (1999) 2.24
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Heat flow and distribution during induction of general anesthesia. Anesthesiology (1995) 2.12
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Cyclin partners determine Pho85 protein kinase substrate specificity in vitro and in vivo: control of glycogen biosynthesis by Pcl8 and Pcl10. Mol Cell Biol (1998) 2.04
A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A (1997) 2.04
Healing rituals and sacred serpents. Lancet (1992) 2.03
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96
Crystal structure of the Xrcc4 DNA repair protein and implications for end joining. EMBO J (2000) 1.94
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res (1983) 1.91
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol (2001) 1.89
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2. Mol Cell Biol (1997) 1.89
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia (1994) 1.87
A regulator of transcriptional elongation controls vertebrate neuronal development. Nature (2000) 1.87
Structural basis for MutH activation in E.coli mismatch repair and relationship of MutH to restriction endonucleases. EMBO J (1998) 1.84
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A (2001) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Linearly polarized emission from colloidal semiconductor quantum rods. Science (2001) 1.82
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Neuropeptide FF and FMRFamide potentiate acid-evoked currents from sensory neurons and proton-gated DEG/ENaC channels. Neuron (2000) 1.81
mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res (1998) 1.78
Development of child-centered disease-specific questionnaires for living with asthma. Psychosom Med (1994) 1.78
Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J (2005) 1.74
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes (1994) 1.73
Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia (2010) 1.68
Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol (1996) 1.68
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
Density-functional theory of the electronic structure of molecules. Annu Rev Phys Chem (1995) 1.64
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Pharmacogenetics and cancer therapy. Nat Rev Cancer (2001) 1.62
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62